This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
undefined
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
You are about to leave bmsstudyconnect.com. The site you are linking to is not controlled or endorsed by Bristol Myers Squibb and Bristol Myers Squibb is not responsible for the content provided on that site.
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
This link takes you to a website of Bristol Myers Squibb that may have a different purpose, may have different terms and conditions, and is being provided solely to enable you to contact Bristol Myers Squibb.
Active, Not Recruiting
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer - CA224-106
Updated:
12 February, 2025
|
ClinicalTrials.gov
Phase
Gender(s)
Age Range
Active, Not Recruiting
Inclusion Criteria: - Histologically confirmed advanced/metastatic hepatocellular carcinoma (HCC) - Naïve to systemic therapy for advanced/metastatic HCC (prior neo-adjuvant or adjuvant immunotherapy is permitted if recurrence occurs ≥ 6 months after treatment completion and the case is discussed with BMS medical team) - Child-Pugh score of 5 or 6 (ie, Child-Pugh A) - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Exclusion Criteria: - Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC - Prior allogenic stem cell or solid organ transplantation - Untreated symptomatic central nervous system (CNS) metastases - Clinically significant ascites as defined by: i) Prior ascites that required treatment and requires on-going prophylaxis, or ii) Current ascites requiring treatment Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
466-SE-2100058